Brought to you by 
Knoll and Tularik to develop obesity drugs
07 May 2002
Executive Summary
Tularik Inc. (gene expression) entered a five-year collaboration with BASF AG's subsidiary Knoll AG (pharmaceuticals) in the area of obesity to discover and develop drugs that act on novel regulatory targets in energy metabolism pathways.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Knoll and Tularik to develop obesity drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice